Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2014
At a glance
- Drugs Lenalidomide (Primary)
- Indications Graft-versus-host disease; Multiple myeloma
- Focus Adverse reactions
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jan 2012 Planned end date changed from 1 Feb 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 20 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.